3 Hospital Network, Cardiac Care and Preventive Testing Stocks With a Strong Future Roadmap: Max Healthcare Institute, Narayana Hrudayalaya and Thyrocare Technologies
- October 21, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Max Healthcare Institute, Narayana Hrudayalaya and Thyrocare Technologies: ROE of 13.4% to 27.9% and FY22 to FY26 revenue CAGR of 8.2% to 21.0%. Prices as of 20 Oct 2026.
Quick Answer
The three private healthcare stocks to watch are Max Healthcare Institute, Narayana Hrudayalaya and Thyrocare Technologies. Their return on equity ranges from 13.4% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.2% to 21.0%. Thyrocare Technologies has the highest return on equity at 27.9%, while Narayana Hrudayalaya has the fastest revenue growth at 21.0% a year. Prices are based on the 20 October 2026 close, and this article is educational, not investment advice.
Private healthcare stocks let investors back the organised providers that are taking share from small clinics as families look for trusted treatment. Max Healthcare Institute, Narayana Hrudayalaya and Thyrocare Technologies show three parts of the chain: a multi-specialty hospital network, an affordable cardiac and multi-specialty group and a preventive testing company.
This list covers three private healthcare stocks with complete current figures: Max Healthcare Institute, Narayana Hrudayalaya and Thyrocare Technologies. Every figure comes from the latest reported financials and the 20 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Private Healthcare Stocks?
Private healthcare stocks are listed companies that run hospitals, clinics and laboratories on a commercial basis. Their earnings depend on beds, occupancy, the mix of procedures and the volume of tests handled, so both capacity and case quality matter.
Private Healthcare Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Max Healthcare Institute | 830 | 80,717 | 55.4 | 59.6 | 13.4 | 0.32 |
| Narayana Hrudayalaya | 1,740.9 | 35,603 | 43.6 | 59.6 | 17.8 | 1.29 |
| Thyrocare Technologies | 471 | 7,501 | 42.6 | 59.6 | 27.9 | 0.09 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing private healthcare stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in private healthcare stocks can use the coming numbers to test whether growth is holding.
Why Do Private Healthcare Stocks Have a Strong Roadmap in India?
Private healthcare stocks have a strong roadmap in India because spending on treatment and preventive care is rising faster than the supply of organised beds and laboratories.
- Insurance penetration. More insured families choose private providers for planned procedures and diagnostics.
- Capacity additions. New beds and collection centres in cities with proven demand lift volumes.
- Preventive testing. Wellness packages and routine screening bring regular, repeat customers to labs.
Why Max Healthcare Institute Features Among These Private Healthcare Stocks
Among the private healthcare stocks on this list, Max Healthcare Institute runs a large network of multi-specialty hospitals concentrated in Delhi NCR, Punjab, Uttarakhand and Maharashtra, with a strong presence in oncology, cardiac sciences, neurosciences and orthopaedics.
Revenue rose from Rs 4,059 crore in FY22 to Rs 8,536 crore in FY26, a compound annual growth rate of 20.4%. Net profit grew from Rs 605 crore in FY22 to Rs 1,442 crore in FY26, which works out to a compound annual growth rate of 24.3%.
In the June 2026 quarter, revenue grew 16.6% year on year to Rs 2,407 crore, while net profit rose 4.9% to Rs 323 crore. The company has a return on equity of 13.4%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 80,717 crore. The stock trades at a P/E of 55.4, below the industry P/E of 59.6.
Roadmap: The roadmap rests on adding beds through brownfield expansion at existing campuses and through new hospitals in cities where the group already has referral strength. Higher bed occupancy and a richer case mix lift revenue per occupied bed, which is the number hospital analysts follow most closely.
What to watch: Track how quickly new beds reach stable occupancy and whether average revenue per occupied bed keeps rising.
Why Narayana Hrudayalaya Features Among These Private Healthcare Stocks
Among the healthcare provider shares on this list, Narayana Hrudayalaya, widely known as Narayana Health, is a Bengaluru-based hospital group built around affordable cardiac care that now covers multiple specialities across India and also operates in the Cayman Islands.
Revenue rose from Rs 3,736 crore in FY22 to Rs 7,996 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 342 crore in FY22 to Rs 810 crore in FY26, which works out to a compound annual growth rate of 24.1%.
The company has a return on equity of 17.8%, a debt to equity ratio of 1.29 and a market capitalisation of Rs 35,603 crore. The stock trades at a P/E of 43.6, below the industry P/E of 59.6.
Roadmap: Growth is coming from bed additions across its hospital clusters, a rising share of higher-value specialities and an expanding insurance-led patient base. The group has a track record of running hospitals at high efficiency, which supports margins as scale builds.
What to watch: Keep an eye on occupancy in newly added beds and the payor mix between insurance and cash patients.
Why Thyrocare Technologies Features Among These Private Healthcare Stocks
Among the three companies on this list, Thyrocare Technologies runs a centralised, high-volume testing laboratory in Navi Mumbai and collects samples through a wide partner network of diagnostic centres, pharmacies and franchisees across India.
The company has a return on equity of 27.9%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 7,501 crore. The stock trades at a P/E of 42.6, below the industry P/E of 59.6.
Revenue rose from Rs 618 crore in FY22 to Rs 846 crore in FY26, a compound annual growth rate of 8.2%. Net profit grew from Rs 64.4 crore in FY23 to Rs 163 crore in FY26, which works out to a compound annual growth rate of 36.3%. In the June 2026 quarter, revenue grew 23.5% year on year to Rs 244 crore, while net profit rose 34.1% to Rs 51.3 crore.
Roadmap: The centralised model gives it a low unit cost per test, and the company is adding wellness and preventive health packages along with a growing share of direct-to-consumer bookings. Its partner-led channel lets it scale volumes without building its own collection centres.
What to watch: Track growth in test volume per day and the share of revenue from preventive health packages.
Max Healthcare Institute vs Narayana Hrudayalaya vs Thyrocare Technologies on Key Financials
The table below sets the three private healthcare stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Max Healthcare Institute | 4,059 | 8,536 | 20.4% | 1,442 | 16.9% |
| Narayana Hrudayalaya | 3,736 | 7,996 | 21.0% | 810 | 10.1% |
| Thyrocare Technologies | 618 | 846 | 8.2% | 163 | 19.2% |
Thyrocare Technologies posts the highest return on equity in this group at 27.9%. Max Healthcare Institute has the largest FY26 revenue at Rs 8,536 crore, and Narayana Hrudayalaya shows the fastest revenue growth with a 21.0% compound annual rate. A useful habit with private healthcare stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Private Healthcare Stocks
Every theme carries risks that deserve a check before any decision. For these private healthcare stocks, the main points are: Long-term healthcare provider shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Ramp-up timing. New hospitals take time to reach stable occupancy, so profit can lag capacity.
- Doctor availability. Hospitals rely on specialists, and attracting them is central to growth.
- Pricing rules. Changes in insurance tariffs or government price limits can affect revenue per patient.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter private healthcare stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Private Healthcare Stocks
Private healthcare stocks reward investors who follow bed additions, occupancy and test volumes together. Max Healthcare Institute, Narayana Hrudayalaya and Thyrocare Technologies each pair a clear service model with a visible expansion path. Based on the 20 October 2026 close, Max Healthcare Institute trades at Rs 830, Narayana Hrudayalaya at Rs 1,740.9 and Thyrocare Technologies at Rs 471. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these private healthcare stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track private healthcare stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are private healthcare stocks?
Ans. Private healthcare stocks are listed companies that run hospitals, clinics and laboratories on a commercial basis. Their earnings depend on beds, occupancy, the mix of procedures and the volume of tests handled, so both capacity and case quality matter. This list looks at three of them, Max Healthcare Institute, Narayana Hrudayalaya and Thyrocare Technologies, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.
Which private healthcare stocks are covered in this list?
Ans. This list covers Max Healthcare Institute, Narayana Hrudayalaya and Thyrocare Technologies. Based on the 20 October 2026 close, Max Healthcare Institute traded at Rs 830, Narayana Hrudayalaya at Rs 1,740.9 and Thyrocare Technologies at Rs 471. Their return on equity ranges from 13.4% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.2% to 21.0%.
Why do private healthcare stocks have a strong future roadmap in India?
Ans. Private healthcare stocks have a strong roadmap in India because spending on treatment and preventive care is rising faster than the supply of organised beds and laboratories. The main drivers are as follows. Insurance penetration. More insured families choose private providers for planned procedures and diagnostics. Capacity additions. New beds and collection centres in cities with proven demand lift volumes. Preventive testing. Wellness packages and routine screening bring regular, repeat customers to labs. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Max Healthcare Institute performed financially?
Ans. Revenue rose from Rs 4,059 crore in FY22 to Rs 8,536 crore in FY26, a compound annual growth rate of 20.4%. Net profit grew from Rs 605 crore in FY22 to Rs 1,442 crore in FY26, which works out to a compound annual growth rate of 24.3%. In the June 2026 quarter, revenue grew 16.6% year on year to Rs 2,407 crore, while net profit rose 4.9% to Rs 323 crore. The company has a return on equity of 13.4%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 80,717 crore. The stock trades at a P/E of 55.4, below the industry P/E of 59.6. Looking ahead, the roadmap rests on adding beds through brownfield expansion at existing campuses and through new hospitals in cities where the group already has referral strength. Higher bed occupancy and a richer case mix lift revenue per occupied bed, which is the number hospital analysts follow most closely.
How has Narayana Hrudayalaya performed financially?
Ans. Revenue rose from Rs 3,736 crore in FY22 to Rs 7,996 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 342 crore in FY22 to Rs 810 crore in FY26, which works out to a compound annual growth rate of 24.1%. The company has a return on equity of 17.8%, a debt to equity ratio of 1.29 and a market capitalisation of Rs 35,603 crore. The stock trades at a P/E of 43.6, below the industry P/E of 59.6. Looking ahead, growth is coming from bed additions across its hospital clusters, a rising share of higher-value specialities and an expanding insurance-led patient base. The group has a track record of running hospitals at high efficiency, which supports margins as scale builds.
How has Thyrocare Technologies performed financially?
Ans. Revenue rose from Rs 618 crore in FY22 to Rs 846 crore in FY26, a compound annual growth rate of 8.2%. Net profit grew from Rs 64.4 crore in FY23 to Rs 163 crore in FY26, which works out to a compound annual growth rate of 36.3%. In the June 2026 quarter, revenue grew 23.5% year on year to Rs 244 crore, while net profit rose 34.1% to Rs 51.3 crore. The company has a return on equity of 27.9%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 7,501 crore. The stock trades at a P/E of 42.6, below the industry P/E of 59.6. Looking ahead, the centralised model gives it a low unit cost per test, and the company is adding wellness and preventive health packages along with a growing share of direct-to-consumer bookings. Its partner-led channel lets it scale volumes without building its own collection centres.
What risks should investors check before buying private healthcare stocks?
Ans. Investors should check a few risks before buying private healthcare stocks. Ramp-up timing. New hospitals take time to reach stable occupancy, so profit can lag capacity. Doctor availability. Hospitals rely on specialists, and attracting them is central to growth. Pricing rules. Changes in insurance tariffs or government price limits can affect revenue per patient. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of private healthcare stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
